The suppliers of the Mantoux in Europe are decreasing. Novartis has announced that it will stop supplying in Italy in a few months. Chiron stopped supplying the UK about 3 years ago. This leaves SSI as almost the only provider for Europe.
There must be a reason for this.
Also, as the market is left to SSI clinicians take the opportunity of the change to look for another methodology, again accelerating the move to IGRAs.
Alex
